論文

国際誌
2020年12月12日

Antihypertensive drug effects according to the pretreatment self-measured home blood pressure: the HOMED-BP study.

BMJ open
  • Hikari Sano
  • ,
  • Azusa Hara
  • ,
  • Kei Asayama
  • ,
  • Seiko Miyazaki
  • ,
  • Masahiro Kikuya
  • ,
  • Yutaka Imai
  • ,
  • Takayoshi Ohkubo

10
12
開始ページ
e040524
終了ページ
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1136/bmjopen-2020-040524

OBJECTIVES: To clarify whether or not the antihypertensive drug effect is proportional to the baseline pretreatment self-measured home blood pressure (HBP) in accordance with the law of initial value (Wilder's law). DESIGN: A post-hoc analysis of a multicentre clinical trial. SETTING: Outpatients across Japan with mild-to-moderate essential hypertension. PARTICIPANTS: Among 3518 randomised participants, 2423 who self-measured HBP during the pretreatment drug-free period (10-28 days after starting fixed-dose antihypertensive monotherapy) with a mean 7.0 years follow-up were eligible. MAIN OUTCOME MEASURES: We analysed individual HBP readings during pretreatment and monotherapy. RESULTS: The day-to-day HBP during both the pretreatment period and monotherapy period remains almost the same throughout each period; the results were consistent, regardless of the pretreatment HBP. Following monotherapy, the reduction in the HBP increased by 2.2 mm Hg (95% CI: 1.8 to 2.5 mm Hg) per 10 mm Hg pretreatment HBP increase, up to 11.0 mm Hg (95% CI: 9.9 to 12.0 mm Hg) among patients with an HBP ≥165 mm Hg during pretreatment. Among the 1005 patients receiving low-dose monotherapy (defined daily dose: 0.5 units), the reduction peaked at 8.9-9.1 mm Hg in those with pretreatment HBP 155-164 mm Hg and ≥165 mm Hg (p=0.88). CONCLUSIONS: According to Wilder's law, the HBP reduction due to fixed-dose monotherapy was proportional to the pretreatment HBP without any regression to the mean phenomenon. With low-dose antihypertensive drugs, however, the HBP reduction peaked in patients with a high pretreatment HBP, indicating the need for such patients to receive a sufficient amount of antihypertensive drug medication at the initial treatment. TRIAL REGISTRATION: UMIN Clinical Trial Registry (http://www.umin.ac.jp/ctr), Unique identifier: C000000137.

リンク情報
DOI
https://doi.org/10.1136/bmjopen-2020-040524
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33310801
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735093
ID情報
  • DOI : 10.1136/bmjopen-2020-040524
  • PubMed ID : 33310801
  • PubMed Central 記事ID : PMC7735093

エクスポート
BibTeX RIS